Takeda Wins One Loses Another With U.S. FDA Approval Of Edarbi, Japan Withdrawal Of Dasen

TOKYO - Takeda Pharmaceutical Co. is feeling the ups and downs of drug making having announced U.S. FDA approval of the angiotensin II receptor blocker Edarbi days after announcing the withdrawal of its long-time anti-inflammatory drug Dasen from the Japanese market